Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
Want to see ZNTL full AI Analyst Report?
ZNTL Stock Chart & Stats
$1.41
-$0.17(-5.69%)
At close: 4:00 PM EST
$1.41
-$0.17(-5.69%)
Day’s Range― - ―
52-Week Range$1.13 - $6.95
Previous CloseN/A
Volume750.15K
Average Volume (3M)716.92K
Market Cap
$256.27M
Enterprise Value$287.47M
Total Cash (Recent Filing)$211.76M
Total Debt (Recent Filing)$34.65M
Price to Earnings (P/E)―
Beta3.44
Next Earnings
Aug 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding71,186,350
10 Day Avg. Volume819,524
30 Day Avg. Volume716,917
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.90K
Enterprise Value/Ebitda-2.11
Forecast
1Y Price Target
$7.00Price Target Upside396.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical ProgressAdvancing azenosertib into a global Phase 3 confirmatory study materially reduces development risk versus earlier stages. A well-powered ASPENOVA trial aligned with FDA expectations increases the likelihood of a regulatory path and preserves the company’s strategic optionality to commercialize a targeted therapy if results are positive.
Encouraging Clinical Efficacy & Dose OptimizationRobust signal in multiple studies and a chosen pivotal monotherapy dose support differentiated clinical positioning. Demonstrated activity and manageable safety across monotherapy and taxane combinations expand addressable indications and strengthen the case for biomarker-driven adoption, aiding durable commercial prospects.
Cash Runway And Modest LeverageHaving >$200M of cash with runway into late‑2027 provides the firm time to complete pivotal readouts and regulatory filings without immediate financing pressure. Combined with modest debt levels in the balance sheet, this enhances near‑term financial flexibility to execute late‑stage development plans.
Bears Say
No Recurring RevenueAs a clinical‑stage biotech with no consistent product revenues, the company must rely on external financing and milestone receipts. This structural lack of recurring commercial income increases funding risk and leaves long‑term viability contingent on trial outcomes and future capital raises.
Persistently Negative Cash GenerationSustained large negative operating and free cash flows mean the company consumes cash to fund R&D, forcing reliance on equity/debt financing. Even with an improving burn trend, ongoing negative cash generation raises dilution and refinancing risk, constraining long‑term strategic investments.
Eroding Balance SheetMaterial declines in equity and assets reflect cumulative cash burn and losses, reducing financial resilience. A weakened balance sheet limits the company’s ability to withstand trial setbacks or pursue opportunistic partnerships, increasing the likelihood of dilutive financing or constrained execution if milestones slip.
Zentalis Pharmaceuticals News
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $1.13 and its highest was $6.95 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $256.27M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 61 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.023.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.48.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 71,186,350 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Currently, no hedge funds are holding shares in ZNTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentalis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (396.45% Upside)
$7.00 (396.45% Upside)
Hedge Fund Trend
Decreased
By 263.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.33%
12-Months-Change
Fundamentals
Return on Equity
-53.61%
Trailing 12-Months
Asset Growth
-34.10%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on the discovery and advancement of small molecule therapies designed to treat a range of cancers. The company's pipeline features two primary drug candidates: ZN-c3, an inhibitor of the WEE1 protein tyrosine kinase, and ZN-c5, an oral selective estrogen receptor degrader. ZN-c3 is currently undergoing various trials, including a Phase 2 study for advanced solid tumors, a Phase 1/2 trial for advanced solid tumors when administered as a monotherapy, and an ongoing Phase 1b trial in conjunction with chemotherapy for patients suffering from platinum-resistant ovarian cancer. Additionally, it is being investigated in a Phase 2 monotherapy trial focused on a tumor-agnostic predictive biomarker. ZN-c5 is in a Phase 1/2 clinical trial aimed at advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced/metastatic breast cancer. Beyond these, Zentalis is developing ZN-d5, a selective B-cell lymphoma 2 inhibitor in Phase 1 clinical trials for non-Hodgkin's lymphoma and acute myelogenous leukemia, and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in a Phase 1/2 clinical study for advanced non-small cell lung cancer. The company is also innovating BCL-xL heterobifunctional degraders, specifically designed to utilize E3 ligases not present in platelets, thereby mitigating the dose-limiting thrombocytopenia typically associated with other BCL-xL inhibitors. Incorporated in 2014 and based in New York, New York, Zentalis Pharmaceuticals, Inc. has established licensing agreements and strategic collaborations with partners such as Recurium IP Holdings, LLC, Mayo Foundation for Medical Education and Research, SciClone Pharmaceuticals International (Cayman) Development Ltd., Pfizer, Inc., Eli Lilly and Company, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.
ZNTL Stock 12 Month Forecast
Average Price Target
$7.00
▲(396.45% Upside)
Technical Analysis
MacroGenics
―
VistaGen Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
Ownership Overview
30.09% Insiders
5.96% Mutual Funds
24.08% Other Institutional Investors
34.91% Public Companies and
Individual Investors